IDEXX Laboratories, Inc.

“IDEXX Laboratories is one of the highest-quality businesses in global equities — a vertically integrated, recurring-revenue diagnostics platform with ~55% market share, 40-50% ROIC, expanding margins, and a widening multi-layer moat that no competitor can credibly replicate over the next decade. The structural growth story (global diagnostic underpenetration, aging pet demographics, clinical protocol expansion) is intact. The sole and decisive objection is valuation: at $562 and 34x forward earnings, the stock prices in near-perfection and offers a realistic 5-10 year total return of roughly 5-7% annually — inadequate compensation for the residual uncertainty. Permanent capital impairment risk is exceptionally low; the risk is opportunity cost. IDEXX belongs on every long-term investor's watchlist, and a meaningful entry opportunity will likely emerge during the next market dislocation or growth scare. Target entry near $400-430 for a high-conviction, full-position build.”